ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > LOXL2

LOXL2

概要

Name:Lysyl oxidase homolog 2
Target Synonym:EC:1.4.3.13,EC 1.4.3,Lysyl oxidase-like protein 2,Lysyl oxidase homolog 2,LOXL2,Lysyl Oxidase Like 2,Lysyl Oxidase-Related Protein WS9-14,Lysyl Oxidase-Related Protein 2,Lysyl Oxidase-Like 2 Delta E13,Lysyl Oxidase-Like 2 Protein,Lysyl Oxidase Related 2,Lysyl Oxidase-Like 2,EC 1.4.3.13,WS9-14,LOR2,LOR
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase 2 Clinical

製品リスト製品比較と製品注文

製品仕様別:
製品カテゴリー別:
種類別:
コンジュゲート:
製造番号 種類 製品説明 構造 純度 特徴
LO2-H52H3 Human Human LOXL2 Protein, His Tag (active enzyme)
LO2-H52H3-structure
LO2-H52H3-sds
LO2-H82E3 Human Biotinylated Human LOXL2 Protein, His,Avitag™
LO2-H82E3-structure
ACRO Quality

Synonym Name

Lysyl oxidase homolog 2,LOXL2

Background

Lysyl oxidase homolog 2 is also known as LOXL2, Lysyl oxidase-like protein 2, which is expressed in many tissues, highest expression in reproductive tissues, placenta, uterus and prostate, Up-regulated in a number of cancers cells and tissues. LOXL2 mediates the post-translational oxidative deamination of lysine residues on target proteins leading to the formation of deaminated lysine (allysine). When secreted in extracellular matrix, promotes cross-linking of extracellular matrix proteins by mediating oxidative deamination of peptidyl lysine residues in precursors to fibrous collagen and elastin. LOXL2 acts as a regulator of sprouting angiogenesis, probably via collagen IV scaffolding. When nuclear, acts as a transcription corepressor and specifically mediates deamination of trimethylated 'Lys-4' of histone H3 (H3K4me3), a specific tag for epigenetic transcriptional activation. LOXL2 acts as a regulator of chondrocyte differentiation, probably by regulating expression of factors that control chondrocyte differentiation.

Clinical and Translational Updates

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
PXS-5382 PXS-5382; PXS-5382A Phase 1 Clinical Pharmaxis Ltd Non-alcoholic Fatty Liver Disease; Idiopathic Pulmonary Fibrosis; Renal fibrosis Details
PXS-5338 PXS-5338 Phase 1 Clinical Pharmaxis Ltd Non-alcoholic Fatty Liver Disease; Liver Cirrhosis; Renal fibrosis; Pulmonary Fibrosis Details
GB-2064 PAT-1251; GB-2064 Phase 2 Clinical Pharmakea Inc Polycythemia Vera; Primary Myelofibrosis; Thrombocythemia, Essential Details

This web search service is supported by Google Inc.

totopphone